MedRod® Products
Registered Trademark Developed By Preclinapps
MedRod® for Chronic Dosing
In validated MedRod® implants the active compounds are dispersed in flexible, polymeric cylindrical matrix , typically covered by membrane or coating. The process results in elastic MedRod® where the compounds are safely immobilized and steadily released for several months. MedRod® implants are intended for in vitro or in vivo preclinical studies.
Sustained release solutions for veterinary use
We are constantly developing new solutions for veterinary applications. Novel sustained release solutions for analgesic, obesity, diabetes and many other indications. Our aim is to renew veterinary drug delivery and enable stressless life despite the medication.
Estrone (E1)
For mice and rats in metabolic and breast cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days, specific implants up to several years
Dose range: 0.02 µg – 5 µg/day
17β-estradiol (E2)
For mice and rats in metabolic and breast cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days, specific implants up to several years
Dose range: 0.25 µg – 15 µg/day
Dihydrotestosterone (DHT)
For mice and rats in metabolic and prostate cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days
Dose range: 10 µg – 100 µg/day
Progesterone (P4)
For mice and rats in metabolic and breast cancer xenograft, PDX and syngeneic studies.
Drug release: 50 – 150 days
Dose range: 25 µg – 250 µg/day
Testosterone (TE)
For mice and rats in metabolic and prostate cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days
Dose range: 10 µg – 125 µg/day
Letrozole (LTZ)
For mice and rats in metabolic studies, breast and prostate cancer xenograft, PDX and syngeneic studies and studies related to aromatase inhibitors.
Drug release: At least 100 days, specific implants up to 6 months
Dose range:5 µg – 75 µg/day